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Like all mammalian tissues, skeletal muscle is dependent
on membrane traffic for proper development and homeo-
stasis. This fact is underscored by the observation that
several human diseases of the skeletal muscle are caused
by mutations in gene products of the membrane traffick-
ing machinery. An examination of these diseases and the
proteins that underlie them is instructive both in terms of
determining disease pathogenesis and of understanding
the normal aspects of muscle biology regulated by
membrane traffic. This review highlights our current
understanding of the trafficking genes responsible for
human myopathies.
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Skeletal muscle is a highly specialized tissue with a complex
structure designed for the generation of force. Like all organ
systems, skeletal muscle uses the basal elements of
membrane traffic, including forward transport of newly
synthesized proteins, internalization of receptors and
growth factors, and processing of proteins and membranes
for degradation via the lysosome (1). However, because of
its unusual structure, with individual myofibers containing
multiple nuclei and the majority of the cytoplasm dedicated
to the contractile apparatus, muscle is a unique setting in
which this trafficking machinery operates. The Golgi appa-
ratus, the endoplasmic reticulum and the endosomes are in
tightly restricted regions of the myofiber, and require
extensive organelle rearrangement during myogenesis to
arrive at their location in themature cell (2). In addition, there
are several processes specific to muscle that require
membrane traffic. These include the establishment and
maintenance of the neuromuscular junction (3), the forma-
tion and function of the T-tubule (4), and the generation and
repair of myotubes via membrane and myoblast fusion (5).
The importance of membrane traffic for muscle is high-
lighted by the fact that several muscle diseases are the
result of defects in its machinery. These disorders illumin-
ate some of the specific roles that membrane traffic plays
in the development and maintenance of the myofiber.
Conversely, in certain cases they bring out the disparity
between our general knowledge of trafficking processes
and our specific understanding of the pathogenic mech-
anisms that underlie these diseases. The purpose of this
review was to discuss the muscle disorders caused by
mutations in the trafficking machinery and to describe
the theories related to the functions and abnormalities of
the individual disease-associated gene products. We will
consider the dysferlinopathies (Table 1) (6), the caveolino-
pathies (Table 2) (7), and a family of diseases called
centronuclear myopathies (Figure 1), all of which result
from mutations in several trafficking genes (8).
Dysferlin
Dysferlinopathies
The dysferlinopathies are a spectrum of autosomal reces-
sive muscle diseases caused by mutations in the dysferlin
gene (6). The primary dysferlinopathies are limb girdle
muscular dystrophy (LGMD) type 2B (LGMD2B) and
Miyoshi myopathy (MM) (9,10). LGMD2B is a disorder
characterized by progressive proximal muscle weakness
and atrophy (proximal muscles ¼ shoulder, upper arm,
pelvic and thigh muscles), with onset in adolescence or
early adulthood. MM, however, begins with weakness
and atrophy in the distal posterior muscles (especially the
calf muscles), with spread to the proximal musculature
late in the condition. While the two diseases are clearly
distinct clinical entities, they share some features:
extremely high elevations of creatine kinase (a serum
marker for muscle breakdown), similar age of onset
(mid/late childhood to early adulthood) and slow disease
progression. Several other phenotypes, including hyper-
CKemia, scapuloperoneal syndrome and distal myopathy
with anterior tibial onset have also been reported in
association with dysferlin mutations. HyperCKemia is an
unusual clinical entity in which patients have elevation of




Dysferlin is amember of the ferlin family, a group of related
proteins homologous to the Caenorhabditis elegans gene
Fer-1 (11). All ferlins are characterized by multiple calcium-
binding C2 domains (12). In mammals, dysferlin and
myoferlin are the major ferlins expressed in skeletal
muscle (13). Dysferlin is highly enriched at sites of muscle
membrane injury, and the primary role for dysferlin is in
calcium-mediated membrane repair (12). Dysferlin appears
to facilitate the fusion and incorporation of membrane
vesicles at the site of membrane discontinuity (14). The
mechanism of action through which it promotes this
process is still being elucidated, although it likely involves
the ability of dysferlin to initiate multiple protein–protein
and protein–phospholipid interactions (15). Dysferlin is also
important for myoblast fusion during muscle development.
However, myoferlin appears to be the ferlin most involved
in this process (16).
Dysferlin pathogenesis
Muscle membranes are subjected to dramatic changes
during contraction and are believed to incur microdomain
injuries. These injuries are continually repaired by incorpo-
ration of new membrane vesicles. Mutations in dysferlin
lead to decreased levels of dysferlin protein (6), and lack
of dysferlin likely leads to an inability to repair these
membrane injuries (14). This in turn leads to the muscle
breakdown associated with the dysferlinopathies. This
presumed pathogenic sequence is supported by the
observation in patient biopsies of injured muscle mem-
branes with accumulated unfused submembranous
vesicles (17). It is also corroborated by the observation
that dysferlin mutant mice develop a severe, progressive
muscle disease (14). Interestingly, the levels of dysferlin
protein do not appear to correlate with disease severity
(18). Additionally, individual mutations can be associated
with both LGMD2B and MM (19). Thus, other factors
including modifier genes and physiological features spe-
cific to different muscle groups are predicted to determine
the clinical presentation of dysferlin deficiency.
Caveolin-3
Caveolinopathies
Mutations in caveolin-3 (CAV-3) cause four distinct but
overlapping forms of muscle disease (7). The first charac-
terized was autosomal dominant LGMD 1C, which is
a classic limb girdle dystrophy in that it features pro-
gressive weakness and dysfunction of the proximal mus-
culature (20). LGMD1C most commonly presents in
childhood, and is associated additionally with myalgias
(muscle pains), muscle cramps, and high CK levels.
Mutations in cav3 also cause autosomal dominant rippling
muscle disease (RMD). The clinical features of RMD
(percussion-induced rapid contraction, painful percussion-
induced muscle mounding, and stretch/mechanically-
inducedmuscle rippling) can be present in any combination
in patients with CAV-3 mutations. The age of onset is
widely variable (early childhood to 5th decade). Usually
there is a history of exercise-induced stiffness and cramps
and calf hypertrophy, but there is some irregularity in the
presence of these features. Biopsy often shows variable
fiber size and centralized nuclei. The remaining two
Table 1: Dysferlinopathies [adapted from Aoki (68)]
Subtype Age of onset
(years)
Clinical features Prevalence
LGMD2B 26  9 Slowly progressive proximal muscle weakness 20% of all AR LGMD
MM 21  7 Slowly progressive distal weakness, legs > arms,
calves most affected
UNK
Scapuloperoneal syndrome ? Shoulder girdle, distal legs Rare
Distal myopathy/anterior tibial onset ? Distal weakness, anterior instead of calves Rare
HyperCKemia ? None (occasional calf hypertrophy) UNK
UNK, unknown.
Table 2: Caveolinopathies [adapted from Bruno et al. (69)]
Subtype Age of onset Clinical features Prevalence
LGMD1C Childhood Slowly progressive proximal muscle weakness,
myalgias/cramps
Rare (<1% of LGMDs)
RMD Usually late childhood Percussion-induced muscle mounding,
percussion-induced rapid contraction,
mechanically induced muscle rippling
Rare
Distal myopathy Early adulthood Hand/foot muscle atrophy, elevated CK Single case
HyperCKemia ? None UNK
UNK, unknown.
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conditions associated with CAV3 mutations are hyper-
CKemia and distal myopathy. CAV3 mutations have been
found in sporadic and dominant familial cases of hyper-
CKemia. Distal myopathy as a result of CAV3 mutations is
rare and, as the name implies, characterized by distal
weakness, as opposed to the proximal weakness
observed in LGMD.
CAV-3 function
Caveolins are the core proteins associated with caveolae
(21). Caveolae are 60–80 nm plasma membrane invagin-
ations that mediate the sequestration of certain receptors
and transporters and delivery of their cargo to the endo-
cytic pathway. Caveolins and caveolae are also implicated
in the regulation of lipid homeostasis, cell adhesion and cell
signaling. There are three caveolins, with CAV-3 as the
major muscle-specific isoform (22). Caveolae are inti-
mately associated with the T-tubule network during myo-
genesis (23). In mature muscle, CAV-3 is found in the
sarcolemma, not the T-tubule, and is also found at the
neuromuscular junction (24). The function of CAV-3 has
been defined using gene knockout in mice and gene
knockdown in zebrafish (25,26). CAV-3 knockout mice lack
caveolae in their muscle and have aberrant formation and
organization of their T-tubule network. The knockout mice
also experience myofiber degeneration, although the basis
for this is poorly understood. Zebrafish with reduced levels
of CAV-3 have abnormalities in myoblast fusion, a function
for caveolin further supported by in vitro studies, as well as
myofiber breakdown.
CAV-3 pathogenesis
The CAV-3 mutations associated with human muscle
diseases likely act in a dominant-negative manner. A
number of studies have demonstrated that there is
a greater than 95% reduction in CAV-3 at the plasma
membrane in patients with CAV-3 mutations (7,27). The
mechanism behind this appears to be retention of both
mutant and wild-type CAV-3 in the Golgi apparatus, with
the result being the failure of trafficking of cav-3 to the
plasma membrane. Mouse knockout and zebrafish knock-
down studies (see above) suggest that reduced cav-3
levels can cause muscle disease. However, how the loss
of caveolae results in the specific phenotypes observed in
LGMD and RMD is still unclear. T-tubule abnormalities and
calcium dysregulation may help explain the hyperexcita-
bility and muscle rippling observed in these conditions.
Interestingly, CAV-3 mutations also result in dysferlin
mislocalization to the Golgi apparatus (28). Thus, it is
possible that some or most of the pathophysiology in the
caveolinopathies, in particular in LGMD1C, may be related
to loss of proper dysferlin function.
Figure 1: Centronuclear myopathy.
A, B) Shown are photomicrographs
from hematoxylin/eosin-stained muscle
from an unaffected child (A) and a child
with myotubular myopathy (B). Note
the small fiber size and the abundant cen-
tral nuclei (arrows). (Images courtesy of
Jeff Golden, University of Pennsylvania).
C) List of the genes associated with
centronuclear myopathy. Scale bar ¼
50 mm.
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Centronuclear Myopathies
Centronuclear myopathies are a diverse group of inherited
muscle diseases that share a common pathologic appear-
ance on muscle biopsy. Muscle fibers are characterized by
enlarged, centrally located myonuclei surrounded by a halo
of disorganized cytoplasmic organelles (Figure 1B). This is in
contrast to normal myofibers, where nuclei are at the
periphery and organelles are in a narrowly restricted location
(Figure 1A). It is also distinct in appearance from the
centralized nuclei observed in the muscular dystrophies.
The abnormal fibers in centronuclear myopathy resemble
fetal myotubes, although recent evidence suggests they
accumulate after myogenesis is concluded (see below).
Centronuclear myopathies can present sporadically or else
be inherited in X-linked, autosomal dominant and auto-
somal recessive patterns (Figure 1C) (8). The age of onset
and the severity of presentation differ between the differ-
ent types. The X-linked and autosomal recessive forms
typically present in infancy with severe symptoms, while
most cases of autosomal dominant centronuclear myopa-
thy present in adulthood. Currently, four genes are known
to cause the condition, with several cases not yet ex-
plained (and thus implying the existence of additional
disease genes). Interestingly, despite the differences in
clinical presentation, all known causes of centronuclear
myopathy result in the same pathologic changes and are
because of abnormalities in proteins associated with
membrane traffic. The proposed function(s) of these
genes as well as the possible relationship between these
proteins is discussed below.
Myotubularin
Myotubular myopathy
Myotubular myopathy is an X-linked congenital myopathy
caused by mutations in the myotubularin gene (29). It is
one of the most severe muscle diseases of childhood, with
symptom onset at or around the time of birth. Clinical
characteristics include facial and eye muscle weakness,
diffusely lowmuscle tone and respiratory failure as a result
of diaphragmatic muscle dysfunction. Two-thirds of male
patients die in the first year of life. The remaining boys
often have significant disability. Classic myotubular myo-
pathy is a rare condition, with estimated incidence ap-
proximately 1:50 000. Improved genetic testing, however,
has demonstrated that muscle disease associated with
myotubularin mutations is likely to involve significantly
more clinical presentations (including late onset muscle
weakness in women) with a much higher overall incidence
(30–32).
Myotubularin function
Myotubularin was first described as a protein tyrosine
phosphatase, but it is now clearly established that the
primary function of myotubularin is as a lipid phosphatase
that acts on phosphoinositide (PI) residues (32–34). Speci-
fically, it dephosphorylates phosphoinositide-3-phosphate
(PI3P) to form phosphoinositide monophosphate and de-
phosphorylates phosphoinositide-3,5-phosphate to form
phosphoinositide-5-phosphate (PI5P). PIs are specialized
lipid residues found restricted to various subcellular organ-
elles (33). Their role is to target the localization of proteins
to these organelles, and their modification/regulation is
a critical aspect of regulated membrane traffic. The fact
that myotubularin is a PI phosphatase thus implicates it as
a regulator of membrane traffic.
Myotubularin has been studied extensively in vitro. Exo-
genous expression of the protein reduces PI3P levels, thus
supporting the notion that it is a lipid phosphatase (34,35).
Overexpression results in abnormalities in receptor endo-
cytosis and endosome to lysosome trafficking and in the
pathologic accumulation of endosomal vesicles (36). This
phenotype is consistent with myotubularin’s ability to
dephosphorylate PI3P, which is itself a critical regulator
of endosomal dynamics, and leads to the theory that
myotubularin’s major function is to regulate the movement
of vesicles from the endosome to the lysosome (37).
Myotubularin localizes in cell culture to early and late
endosomes. It also localizes (perhaps more abundantly)
to a dense cytoplasmic network of unclear significance and
can dynamically associate with specialized plasma mem-
brane structures like Rac-induced membrane ruffles (38).
It is thus possible that myotubularin has additional non-
endosomal functions, such as the prevention of inappro-
priate accumulation of PI3P on other organelles/structures
or the regulation of plasmamembrane dynamics by quickly
removing PI3P. Other potential functions for myotubularin
relate to PI5P (39). Phosphatase activity by myotubularin
and its family members is the major mechanism for
generating this PI. This PI is of low abundance and its
function is poorly understood. A recent study suggests
that PI5P has a role in the regulation of the PI3 kinase/Akt
pathway (40).
Myotubularin pathogenesis
An essential role for myotubularin has been confirmed by
a mouse knockout experiment, giving insight into how
myotubularin deficiency leads to human muscle disease.
Buj-Bello et al. found that loss of myotubularin causes
a myotubular myopathy-like disease in mice (41). Their
study provides convincing evidence that the defect is
related to the maintenance of muscle and not its forma-
tion. Myogenesis is successfully completed in the myotu-
bularin knockout mouse, and the pathognomonic changes
associated with myotubular myopathy do not surface until
the mice are at least 2 months old.
While this study shows that myotubularin is essential for
post-development muscle maintenance, to date there
have been no studies in vivo testing the mechanistic
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hypotheses that have been generated by the in vitrowork.
Loss of regulation of endosome to lysosome traffic re-
mains the predominant hypothesis. However, no vacuoles
or endosomal accumulations have been detected in
muscle biopsy samples, nor in myocytes cultures from
myotubular myopathy patients. Furthermore, vacuole for-
mation is not a described feature of other human diseases
caused by mutations in myotubularin-related proteins. In
contrast, it was recently reported that abnormalities in Fig4
and Vac14, two regulators of lipid monophosphates that
act on the 5 phosphate residue, cause neurologic disease
and result in a massive accumulation of pathologic vesicles
(42,43). Thus, vesicle accumulation can result from dysre-
gulation of lipid monophosphates, and why this feature
is absent in cells with myotubularin deficiency remains to
be explained if the endosomal trafficking hypothesis is
correct.
Dynamin-2
Autosomal dominant centronuclear myopathy
Mutations in the large GTPase dynamin-2 are associated
with autosomal dominant centronuclear myopathy (44).
In general, cases of dynamin-2-related centronuclear myo-
pathy are late in onset, with symptoms first appearing in
adolescence or adulthood. The disease is characterized by
a slowly progressive weakness, with distal muscles more
prominently affected than proximal (45). Facial weakness is
a common feature, and some patients exhibit bilateral ptosis
and extraocular eyemuscle involvement. No reduction in life
span is associated with the condition. Recently, additional
mutations in dynamin-2 have been identified in patients with
a more severe form of centronuclear myopathy resembling
myotubular myopathy (46). These patients present with
muscle weakness at birth. In contrast to myotubular myo-
pathy, however, these infants have little or no respiratory
involvement, and have a relatively good prognosis.
Dynamin-2 function
Dynamin 2 is a conventional member of the dynamin
superfamily, sharing particular homology with dynamin 1
and 3. Dynamins 1-3 share a similar structure, with 5
conserved functional domains [GTPase, pleckstrin hom-
ology (PH), middle, proline rich and GTPase effector (GED)]
(47). Dynamins 1 and 3 are restricted in their tissue
distribution, while dynamin-2 is ubiquitously expressed
(48). Dynamins are implicated in the regulation of a variety
of cell and organelle fission events (49). Dynamin-2, in
particular, has long been known to play a key role in
clathrin-mediated endocytosis, thought to function by
forming a ring around vesicle necks and contribute to the
‘pinching’ off of vesicles. Recent observations suggest
that dynamin 2 also functions in a number of cellular
processes not directly related to its role in vesicle fission.
In particular, dynamin 2 interacts with several proteins
involved in the regulation of actin assembly, including
cortactin, syndapins, intersectins, and profilin (50). These
interactions likely assist in coordinating endocytosis, but
they also may contribute to cell functions such as lamelli-
podial extension (51), phagocytosis (52), and cell motility
(53). Dynamin-2 is also a critical player in cytokinesis and
regulation of centrosomal function.
Dynamin-2 pathogenesis
To date, all muscle disease caused by mutations in
dynamin-2 are confined to the middle and PH domains
(Figure 2A). Thesemutations are believed to act in a dominant-
negative manner as limited study of dynamin-2 in patient
fibroblasts revealed no decrease in protein levels (44).
Current understanding of these domains suggests that the
phenotypes caused by mutations in either domain may
result from defective endocytosis. There is evidence that
the middle domain is necessary for assembling dynamin
into the ring-like structures surrounding the necks of
endocytic vesicles (54). The middle domain also interacts
directly with the GED (55), which may be the basis for this
Figure 2: Mutations in centronu-
clear myopathy. A) List of mutations
in dynamin 2. Note that all reported
sequence changes are confined to the
middle and PH domains. Note that the
E368Q mutation* causes both myo-
pathy and peripheral neuropathy (67).
B) List of mutations in amphiphysin 2
(see text for more description).
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requirement in dynamin self-assembly. While the PH
domain of dynamin is not known to have a direct role in
self-assembly, it belongs to a family of domains found in
a wide variety of membrane-associated proteins. Many PH
domains bind PIs with high affinity and specificity. Dyna-
min’s PH domain binds to membrane phospholipids includ-
ing PI(4,5)p2 and PI(3–5)P3 (56). Mutations disrupting
phosphoinositol binding of the PH domain of dynamin-1
block endocytosis (57), which suggests that endocytosis
might also be disrupted in dynamin-2 PH domainmutations.
Little is known about the specific functions of dynamin-2 in
muscle, and the reasons dynamin-2 mutations cause
myopathy remain unknown. Middle domain mutations
have only been reported in the more common, less severe
presentation, while the PH domain mutations are associ-
ated with a severe presentation; it is not clear why this
distinction exists. The original study identifying dynamin-2
mutations in centronuclear myopathy also examined the
consequence of one point mutation on dynamin-2 localiza-
tion (44). They found that mutant dynamin-2 is aberrantly
expressed, and postulate that the mutant protein acts in
a dominant-negative fashion by preventing the proper
transport and localization of the wild-type protein. This is
an intriguing hypothesis; however, no changes in dynamin-
2 levels or localization have been found in fibroblasts or
skeletal muscle from patients.
Amphiphysin 2
Autosomal recessive centronuclear myopathy
Recently, the first gene associated with autosomal reces-
sive centronuclear myopathy was identified (58). Using
a candidate gene approach, Laporte and colleagues found
mutations in amphiphysin 2 (BIN1) in four individuals from
three families with parental consanguinity and presumed
recessive inheritance. The four patients had onset of
weakness in infancy, and the classic features of centronu-
clear myopathy on muscle biopsy. Other features, includ-
ing facial and eye muscle weakness, were variable.
Respiratory failure was reported only in a fifth individual
with a suspected BIN1 mutation. In all, the phenotype
more closely resembles that reported for the severe
dynamin-2 mutations than that of myotubular myopathy.
Amphiphysin 2/BIN1 function
Amphiphysin-2 is part of larger family of proteins containing
a common structural domain called the BAR (Bin1/amphi-
physin/RVS167) domain. The BAR domain dimerizes to form
an arched structure that can readily bind to curved mem-
branes (59). BAR domain proteins are membrane adaptors
whose fundamental function appears to be as sensors of
membrane curvature (60). This function is utilized during late
endocytosis, when amphiphysins bind to the budding
clathrin-coated vesicle and recruit various proteins, including
dynamin (61). The interaction with dynamin occurs via
amphiphysin’s SH3 domain. In addition to regulating endo-
cytosis, amphiphysins are involved in a diverse range of
cellular processes including signal transduction, transcrip-
tional regulation, apoptosis and vesicle fusion (60).
Amphiphysin-2 is a ubiquitously expressed but has several
different tissue-specific isoforms. The muscle-specific iso-
form, called M-amphiphysin-2, is highly expressed during
myogenesis and in adult muscle and localizes to mem-
brane subdomains including T-tubules (62). It is unique
among amphiphysin-2 isoforms in that it lacks a domain
that is important for binding clathrin-coated vesicles and
regulating endocytosis, and instead contains a novel exon
(exon 10) that promotes association with PI(4,5)P2 at the
plasmamembrane. De Camilli and co-workers, in a seminal
study published in 2002, discovered that M-amphiphysin is
able to independently promote tubule evagination, a func-
tion utilized in vivo for the biogenesis of T-tubules (63).
Knockdown of M-amphiphysin-2 in C2C12 myoblasts
prevents myoblast fusion (63), while gene knockout in
mice results in a severe, lethal cardiomyopathy (64).
Amphiphysin pathogenesis
The mechanisms underlying amphiphysin dysfunction are
the best understood among the centronuclear myopathies.
An extensive study by Laporte and colleagues, building on
their previous work on dynamin-2 as well as the studies by
De Camilli and others, identified the disease-causing muta-
tions in the amphiphysin-2 gene and discovered important
clues about their pathogenesis (Figure 2B) (58). Two of the
reported mutations occur in the BAR domain and cause the
elimination of the ability of the protein to promote tubulation
ex vivo. The other two mutations occur in the SH3 domain.
The resulting proteins are unable to interact with dynamin-2
and in turn prevent the association of dynamin-2 with the
T-tubule network. The authors thus hypothesize that muta-
tions in amphiphysin-2, either by directly interfering with its
tubulation function or by eliminating the important interac-
tion with dynamin-2, disrupt the formation andmaintenance
of the T-tubule network. This study found via immunostain-
ing ofmuscle biopsies that the network is, in fact, disrupted.
What is not clear, however, is whether alteration in the
tubule network is what causes the muscle pathology in
patients with centronuclear myopathy. In addition, as the
authors point out, this mechanism does not explain how
amphiphysin dysfunction results in the most characteristic
pathologic change, the development of central nuclei. This
is also true for dynamin-2 and myotubularin, where involve-
ment in the trafficking pathways cannot explain the forma-
tion of the very unusual appearance of the muscle. Whether
the centronuclear phenotype results from a novel functional
pathway of these proteins, or whether instead it is an
epiphenomenon of disease, remains to be determined.
Sporadic Centronuclear Myopathies
Many cases of centronuclear myopathy occur without an
obvious pattern of inheritance. Within those cases, some
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boys have mutations in myotubularin. The remaining cases
have been difficult to classify genetically. Mutations in two
additional genes have been reported in individual patients
with centronuclear myopathy. One is in the ryanodine
receptor (RYR1), a gene important for the regulated
release of calcium stores (65). Abnormalities in RYR1 are
more commonly associated with another congenital myo-
pathy called central core disease. The other is the hJumpy
gene. Two patients have been found with mutations in this
gene, which was uncharacterized prior to the mutation
report (66). The authors who discovered the mutations
determined that hJumpy is a lipid phosphatase with
enzymatic activity identical to that of myotubularin, and
that the observed sequence changes reduce hJumpy’s
phosphatase activity in vitro. The gene otherwise does not
share myotubularin’s other functional domains and is not
a member of the myotubularin family. This finding again
demonstrates that myotubularin-like phosphatase activity
is critical for muscle function and for disease pathogenesis
in centronuclear myopathy. Further work needs to be
carried out to establish hJumpy‘s role in vitro and in vivo.
In addition, the relationship between hJumpy and myotu-
bularin is unknown; it is not clear if they have overlapping
functions and act on the same pool of PIs, or if instead they
have different spatial and temporal functions.
Summary
At the present time, mutations in six components of the
membrane traffic machinery have been identified that
result in muscle disease. They can be broken down broadly
into two groups, those causing LGMD and those causing
centronuclear myopathy. Given that mutations in three of
the six were only discovered in the past 2 years, we are
likely only scratching the surface in terms of the associ-
ation between membrane traffic and muscle function and
pathology. Currently, no common theme or definite path-
way that links all six genes has been uncovered. The
finding of dysfunction of the T-tubule network in several
of the cases suggests there may be a common pathway in
which these components are involved. Furthermore,
it underscores the importance of membrane traffic for
T-tubule biogenesis and homeostasis, although it is still
unclear how T-tubule biology is an important aspect of the
pathogenesis or why membrane traffic is so important for
muscle function. It seems likely, as parallel studies on the
fundamental cell biology of trafficking and muscle merge
with human genetics, that a deeper understanding of the
normal and pathologic processes will emerge.
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